Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for T&R Biofab Co., Ltd. (246710:KRX), powered by AI.
T&R Biofab Co., Ltd. is currently trading at ₩2,100. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for T&R Biofab Co., Ltd. on Alpha Lenz.
T&R Biofab Co., Ltd.'s P/E ratio is -3.0.
“T&R Biofab Co., Ltd. trades at a P/E of -3.0 (undervalued) with modest ROE of -147.8%. 3Y revenue CAGR of 67.3% highlights clear growth momentum.”
Ask for details →T&R Biofab Co., Ltd. is a prominent player in the field of biotechnology, focusing on the development and commercialization of innovative regenerative medicine and bioengineering solutions. The company specializes in producing bio-printed tissues and organs, contributing significantly to advancements in medical science and treatment methodologies. By leveraging sophisticated 3D bioprinting technology, T&R Biofab aims to address critical healthcare needs and enhance patient outcomes around the globe. The firm's expertise extends to various applications, including drug testing and tissue implants, catering primarily to the healthcare and pharmaceutical industries. Situated in a rapidly evolving sector, T&R Biofab is integral to the ongoing transformation of personalized medicine and the medical device landscape, underscoring its importance in biotechnological and clinical advancements.
“T&R Biofab Co., Ltd. trades at a P/E of -3.0 (undervalued) with modest ROE of -147.8%. 3Y revenue CAGR of 67.3% highlights clear growth momentum.”
Ask for details →T&R Biofab Co., Ltd. (ticker: 246710) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 93 employees. Market cap is $103.2B.
The current price is ₩2,100 with a P/E ratio of -2.95x and P/B of 4.47x.
ROE is -147.79% and operating margin is -31.78%. Annual revenue is $27.0B.